← Human Trials & Peer-Reviewed Studies
Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion.
Plain-language guide to PMID 21994957 (2011): open-label randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 21994957
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2011
- Study type
- Randomized Controlled Trial
- Authors
- Živičnjak M et al. (13 authors)
- DOI
- 10.1210/jc.2011-0399
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Their objective was to analyze the effects of GH treatment on stature and lengths of linear body segments in short children with XLH.
Why It Was Studied
Children with X-linked hypophosphatemic rickets (XLH) are prone to progressive disproportionate stunting despite oral phosphate and vitamin D treatment.
Who Took Part
The age groups tagged for this paper are young children and children, both men and women.
A 3-yr randomized controlled open-label GH study in short prepubertal children with XLH (n = 16) on phosphate and calcitriol treatment was conducted.
A cohort of XLH patients (n = 76) on conservative treatment served as an XLH reference population.
How the Study Was Run
In design terms this was a randomized and open-label study.
The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the participants and staff both knew the treatment.
What Was Measured
Topics PubMed links to this paper include Body Height, Familial Hypophosphatemic Rickets, Genetic Diseases, X-Linked, Growth Disorders and Human Growth Hormone.
What This Means in Plain Language
The paper is a randomized and open-label study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2011 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.